Teladoc Health Stock Forecast, Price & News

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TDOC shares have increased by 43.0% and is now trading at $196.45.
View which stocks have been most impacted by COVID-19.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 10 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Teladoc Health or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Teladoc Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teladoc Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Teladoc Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Teladoc Health.

Teladoc Health, Inc. (NYSE:TDOC) announced its quarterly earnings data on Wednesday, October, 28th. The health services provider reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.10. The health services provider had revenue of $288.81 million for the quarter, compared to analysts' expectations of $281.54 million. Teladoc Health had a negative return on equity of 9.54% and a negative net margin of 13.22%.
View Teladoc Health's earnings history.

Teladoc Health issued an update on its fourth quarter 2020 After-Hours earnings guidance on Tuesday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $369-379 million, compared to the consensus revenue estimate of $347.16 million.

28 Wall Street analysts have issued 1-year price objectives for Teladoc Health's stock. Their forecasts range from $80.00 to $305.00. On average, they expect Teladoc Health's share price to reach $223.07 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for Teladoc Health.

Some companies that are related to Teladoc Health include AstraZeneca PLC (AZN.L) (AZN), Commonwealth Bank of Australia (CSLLY), GlaxoSmithKline (GSK), Stryker (SYK), Intuitive Surgical (ISRG), Anthem (ANTM), Zoetis (ZTS), Gilead Sciences (GILD), GlaxoSmithKline plc (GSK.L) (GSK), Becton, Dickinson and (BDX), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY) and Humana (HUM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), Shopify (SHOP), DocuSign (DOCU), salesforce.com (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

(TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (7.18%), ARK Investment Management LLC (2.43%), State Street Corp (1.81%), Arrowstreet Capital Limited Partnership (1.33%), Nikko Asset Management Americas Inc. (1.25%) and First Trust Advisors LP (1.22%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, David L Shedlarz, David William Sides, Gabriel R Cappucci, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Mark Hirschhorn, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen, Stephany Verstraete and William H Frist.
View institutional ownership trends for Teladoc Health.

TDOC stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Charles Schwab Investment Management Inc., Peregrine Capital Management LLC, Riverbridge Partners LLC, Cubist Systematic Strategies LLC, Westwood Management Corp IL, Spence Asset Management, and Assenagon Asset Management S.A.. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, David L Shedlarz, David William Sides, Gabriel R Cappucci, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Stephany Verstraete, and William H Frist.
View insider buying and selling activity for Teladoc Health.

TDOC stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, ARK Investment Management LLC, Nikko Asset Management Americas Inc., Thrivent Financial for Lutherans, Nuveen Asset Management LLC, Blair William & Co. IL, Natixis, and AQR Capital Management LLC.
View insider buying and selling activity for Teladoc Health.

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TDOC stock can currently be purchased for approximately $196.45.

Teladoc Health has a market capitalization of $28.48 billion and generates $553.31 million in revenue each year. The health services provider earns $-98,860,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Teladoc Health employs 3,276 workers across the globe.

The official website for Teladoc Health is www.teladochealth.com.

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]